While MEK depletion in cancer cells increased tumor immunogenicity and enhanced T cell infiltration, systemic high-dose MEK inhibition impaired T cell activation, which could be reversed by engagement of costimulatory receptors such as 4-1BB, CD40, and OX40 (51–55). The gene discussed is TNFRSF9; the disease is cancer.